TABLE 3.
In vivo efficacy of JPC-2997 and reference antimalarials administered orally either daily or twice daily over 3 days in mice infected with the Plasmodium berghei KBG-173 strain in the modified Thompson test
| Administration and compound | Dose (mg/kg) | Total dose (mg/kg) | Median survival time (days) | No. of mice alive at day 31 (n = 7) | % cured on day 31a |
|---|---|---|---|---|---|
| Once dailyb | |||||
| JPC-2997 | 8 | 24 | >31 | 7 | 100 |
| JPC-2997 | 4 | 12 | 19 | 6 | 86 |
| Piperaquine | 8 | 24 | 24 | 5 | 71 |
| Piperaquine | 4 | 12 | 21 | 4 | 57 |
| Dihydroartemisinin | 64 | 192 | 18 | 0 | 0 |
| Twice daily | |||||
| JPC-2997 | 8 | 48 | >31 | 7 | 100 |
| JPC-2997 | 2 | 12 | 25 | 6 | 71 |
| WR-194,965 | 8 | 48 | 23 | 4 | 57 |
| WR-194,965 | 2 | 12 | 17 | 0 | 0 |
| Piperaquine | 8 | 48 | >31 | 7 | 100 |
| Piperaquine | 2 | 12 | 22.5 | 5 | 71 |
| Chloroquine | 32 | 192 | 16 | 0 | 0 |
| Dihydroartemisinin | 32 | 192 | 18 | 1 | 14 |
a
Percentage of mice that were blood film negative on day 31 after the start of drug treatment.
b
Single daily doses of WR-194,965 and chloroquine were not assessed.